US › Healthcare

BioRestorative Therapies Inc (BRTX)

US · Healthcare · Biotechnology

$1.54+5.48%

Last close · 2026-10-16

Latest quarter · ended 2026-03-31

Revenue

$23,170

Revenue YoY

-7.3%

Net profit

$-2.2M

EPS

$-0.12

EPS estimate

$-0.30

Net margin

-9,298.3%

EPS came in at -0.12 against a street estimate of -0.30 — a beat of 60.0%.

Key statistics

Market cap

$2.1M

Forward P/E

0.0

P/B

1.17

Book value

$2.38

EPS (TTM)

$-21.40

52-week high

$2.93

52-week low

$0.14

50-day MA

$3.06

200-day MA

$7.40

Beta

0.85

Analyst view

Analysts rate BioRestorative Therapies Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $300.00.

Shareholding

Insiders

6.22%

Institutions

13.78%

Largest institutional holders

Fund	Stake
Jane Street Group LLC	2.91%
HRT FINANCIAL LLC	2.57%
XTX Topco Ltd	1.04%
Citadel Advisors Llc	0.99%
Vanguard Fiduciary Trust Co	0.66%
Geode Capital Management, LLC	0.55%
Citigroup Inc	0.23%
Wealth Alliance, LLC	0.14%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioRestorative Therapies Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.